<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04447131</url>
  </required_header>
  <id_info>
    <org_study_id>SDC 5089/20/118</org_study_id>
    <nct_id>NCT04447131</nct_id>
  </id_info>
  <brief_title>Effect of COVID-19 on Platelet Aggregation</brief_title>
  <official_title>Effect of SARS-CoV-2 Infection on Platelet Aggregation and Other Coagulation Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a mechanistic, observational, prospective, case and control study, to compare&#xD;
      platelet aggregation, analyzed by Multiplate-ADP, in hospitalized patients diagnosed with&#xD;
      COVID-19 versus healthy controls. Thus will be included 60 patients who present with&#xD;
      respiratory symptoms within 72 hours of hospitalization and confirmation of the diagnosis of&#xD;
      COVID-19 by laboratory method (RT -PCR and / or positive serology for SARS-CoV-2 - COVID&#xD;
      group); this group will be compared to 60 healthy individuals (asymptomatic and with negative&#xD;
      SARS-CoV-2 serology), matched by sex and age to the previous group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is strong evidence that SARS-CoV-2 infection is associated with atherothrombotic&#xD;
      phenomena. However, platelet activity in COVID-19 has not yet been studied.&#xD;
&#xD;
      Thus, the main objective of this project is to evaluate platelet aggregation by the&#xD;
      Multiplate-ADP method in hospitalized patients diagnosed with COVID-19, in comparison with&#xD;
      the platelet aggregation evaluated by the same method in healthy controls.&#xD;
&#xD;
      Secondary objectives include the assessment of parameters related to coagulation,&#xD;
      inflammation, and clinical outcome variables.&#xD;
&#xD;
      This is a mechanistic, observational, prospective, case and control study, which will include&#xD;
      60 patients who present with respiratory symptoms within 72 hours of hospitalization and&#xD;
      confirmation of the diagnosis of COVID-19 by laboratory method (RT -PCR and / or positive&#xD;
      serology for SARS-CoV-2 - COVID group); this group will be compared to 60 healthy individuals&#xD;
      (asymptomatic and with negative SARS-CoV-2 serology), matched by sex and age to the previous&#xD;
      group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet aggregation analyzed by Multiplate-ADP</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare platelet aggregation analyzed by Multiplate-ADP in hospitalized patients diagnosed with COVID-19 versus healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19.</measure>
    <time_frame>at inclusion,</time_frame>
    <description>Compare platelet aggregation by Multiplate-ADPMultiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19 research.</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare platelet aggregation by Multiplate-ADP, Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the levels of the reticulated platelet fraction in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation versus time (days) of total hospitalization and in the ICU</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) with the time (days) of total hospitalization and in the ICU;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU</measure>
    <time_frame>at inclusion</time_frame>
    <description>Correlate the levels of the reticulated platelet fraction with the time (days) of total hospitalization and in the ICU;</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>COVID-19</arm_group_label>
    <description>Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Individuals</arm_group_label>
    <description>Asymptomatic and with negative SARS-CoV-2 serology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respiratory symptoms but negative for COVID-19</arm_group_label>
    <description>Negative for SARS-CoV-2. But with respiratory symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>venipuncture in peripheral vein</intervention_name>
    <description>single vacuum venipuncture in peripheral vein</description>
    <arm_group_label>COVID-19</arm_group_label>
    <arm_group_label>Healthy Individuals</arm_group_label>
    <arm_group_label>Respiratory symptoms but negative for COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with up to 72 hours of hospitalization for respiratory symptoms, tested with RT-&#xD;
        PCR for respiratory viruses, will be evaluated for inclusion. Patients with diagnostic&#xD;
        criteria for COVID-19 will be considered a case group (COVID-19 group) and will be compared&#xD;
        to two other groups: patients hospitalized for respiratory symptoms with a negative test&#xD;
        for SARS-CoV-2, and healthy control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreement to sign the Free and Informed Consent Form (ICF).&#xD;
&#xD;
          -  Case group: patients with up to 72 hours of hospitalization for respiratory symptoms.&#xD;
&#xD;
          -  Control group: healthy volunteers, defined as having no history (confirmed or&#xD;
             suspected) of COVID-19 or chronic diseases (except hypertension, obesity,&#xD;
             dyslipidemia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known platelet dysfunction or platelet count &lt;100,000 / µL or&gt; 450,000 / µL;&#xD;
&#xD;
          -  Terminal illness;&#xD;
&#xD;
          -  Known liver disease or clotting disorder;&#xD;
&#xD;
          -  Hematocrit less than 34% or greater than 55%;&#xD;
&#xD;
          -  Previous use of antiplatelet agents and / or anticoagulants (except acetylsalicylic&#xD;
             acid and prophylactic heparin);&#xD;
&#xD;
          -  Patients on invasive mechanical ventilation or receiving high oxygen flow.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Carlos Nicolau</last_name>
      <phone>551126615058</phone>
      <email>josecarlosnicolau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de infectologia Emílio Ribas</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Walter Moisés T Braga, MD</last_name>
      <phone>(11) 99181-0931</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090.</citation>
    <PMID>29365305</PMID>
  </reference>
  <reference>
    <citation>Hottz ED, Bozza FA, Bozza PT. Platelets in Immune Response to Virus and Immunopathology of Viral Infections. Front Med (Lausanne). 2018 Apr 30;5:121. doi: 10.3389/fmed.2018.00121. eCollection 2018.</citation>
    <PMID>29761104</PMID>
  </reference>
  <reference>
    <citation>McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):99-117. doi: 10.2174/187152908784533739.</citation>
    <PMID>18537597</PMID>
  </reference>
  <reference>
    <citation>Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 Feb;10(2):83-92. doi: 10.1016/S1473-3099(09)70331-7.</citation>
    <PMID>20113977</PMID>
  </reference>
  <reference>
    <citation>Rondina MT, Brewster B, Grissom CK, Zimmerman GA, Kastendieck DH, Harris ES, Weyrich AS. In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest. 2012 Jun;141(6):1490-1495. doi: 10.1378/chest.11-2860. Epub 2012 Mar 1.</citation>
    <PMID>22383669</PMID>
  </reference>
  <reference>
    <citation>Le VB, Schneider JG, Boergeling Y, Berri F, Ducatez M, Guerin JL, Adrian I, Errazuriz-Cerda E, Frasquilho S, Antunes L, Lina B, Bordet JC, Jandrot-Perrus M, Ludwig S, Riteau B. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am J Respir Crit Care Med. 2015 Apr 1;191(7):804-19. doi: 10.1164/rccm.201406-1031OC.</citation>
    <PMID>25664391</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.</citation>
    <PMID>32139904</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002.</citation>
    <PMID>10075613</PMID>
  </reference>
  <reference>
    <citation>Rubak P, Villadsen K, Hvas AM. Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb Res. 2012 Sep;130(3):420-3. doi: 10.1016/j.thromres.2012.06.017. Epub 2012 Jul 17.</citation>
    <PMID>22809844</PMID>
  </reference>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>May 31, 2023</last_update_submitted>
  <last_update_submitted_qc>May 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Jose Carlos Nicolau</investigator_full_name>
    <investigator_title>Director of Coronary Care Unit</investigator_title>
  </responsible_party>
  <keyword>Platelet aggreggation</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Multiplate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04447131
org study id: SDC 5089/20/118
nct id: NCT04447131
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a mechanistic, observational, prospective, case and control study, to compare
      platelet aggregation, analyzed by Multiplate-ADP, in hospitalized patients diagnosed with
      COVID-19 versus healthy controls. Thus will be included 60 patients who present with
      respiratory symptoms within 72 hours of hospitalization and confirmation of the diagnosis of
      COVID-19 by laboratory method (RT -PCR and / or positive serology for SARS-CoV-2 - COVID
      group); this group will be compared to 60 healthy individuals (asymptomatic and with negative
      SARS-CoV-2 serology), matched by sex and age to the previous group.
There is strong evidence that SARS-CoV-2 infection is associated with atherothrombotic
      phenomena. However, platelet activity in COVID-19 has not yet been studied.

      Thus, the main objective of this project is to evaluate platelet aggregation by the
      Multiplate-ADP method in hospitalized patients diagnosed with COVID-19, in comparison with
      the platelet aggregation evaluated by the same method in healthy controls.

      Secondary objectives include the assessment of parameters related to coagulation,
      inflammation, and clinical outcome variables.

      This is a mechanistic, observational, prospective, case and control study, which will include
      60 patients who present with respiratory symptoms within 72 hours of hospitalization and
      confirmation of the diagnosis of COVID-19 by laboratory method (RT -PCR and / or positive
      serology for SARS-CoV-2 - COVID group); this group will be compared to 60 healthy individuals
      (asymptomatic and with negative SARS-CoV-2 serology), matched by sex and age to the previous
      group.
observational model: Case-Control
time perspective: Prospective
measure: Platelet aggregation analyzed by Multiplate-ADP
time frame: at inclusion
description: Compare platelet aggregation analyzed by Multiplate-ADP in hospitalized patients diagnosed with COVID-19 versus healthy controls.
measure: Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.
time frame: at inclusion
description: Compare platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.
measure: Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.
time frame: at inclusion
description: Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.
measure: Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19.
time frame: at inclusion,
description: Compare platelet aggregation by Multiplate-ADPMultiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19.
measure: Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19 research.
time frame: at inclusion
description: Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for COVID-19.
measure: Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.
time frame: at inclusion
description: Compare platelet aggregation by Multiplate-ADP, Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.
measure: Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.
time frame: at inclusion
description: Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.
measure: Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization
time frame: at inclusion
description: Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization
measure: Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization
time frame: at inclusion
description: Compare the levels of the reticulated platelet fraction in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization;
measure: Platelet aggregation versus time (days) of total hospitalization and in the ICU
time frame: at inclusion
description: Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) with the time (days) of total hospitalization and in the ICU;
measure: Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU
time frame: at inclusion
description: Correlate the levels of the reticulated platelet fraction with the time (days) of total hospitalization and in the ICU;
arm group label: COVID-19
description: Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
arm group label: Healthy Individuals
description: Asymptomatic and with negative SARS-CoV-2 serology
arm group label: Respiratory symptoms but negative for COVID-19
description: Negative for SARS-CoV-2. But with respiratory symptoms
intervention type: Other
intervention name: venipuncture in peripheral vein
description: single vacuum venipuncture in peripheral vein
arm group label: COVID-19
arm group label: Healthy Individuals
arm group label: Respiratory symptoms but negative for COVID-19
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
country: Brazil
citation: Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090.
PMID: 29365305
citation: Hottz ED, Bozza FA, Bozza PT. Platelets in Immune Response to Virus and Immunopathology of Viral Infections. Front Med (Lausanne). 2018 Apr 30;5:121. doi: 10.3389/fmed.2018.00121. eCollection 2018.
PMID: 29761104
citation: McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):99-117. doi: 10.2174/187152908784533739.
PMID: 18537597
citation: Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 Feb;10(2):83-92. doi: 10.1016/S1473-3099(09)70331-7.
PMID: 20113977
citation: Rondina MT, Brewster B, Grissom CK, Zimmerman GA, Kastendieck DH, Harris ES, Weyrich AS. In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest. 2012 Jun;141(6):1490-1495. doi: 10.1378/chest.11-2860. Epub 2012 Mar 1.
PMID: 22383669
citation: Le VB, Schneider JG, Boergeling Y, Berri F, Ducatez M, Guerin JL, Adrian I, Errazuriz-Cerda E, Frasquilho S, Antunes L, Lina B, Bordet JC, Jandrot-Perrus M, Ludwig S, Riteau B. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am J Respir Crit Care Med. 2015 Apr 1;191(7):804-19. doi: 10.1164/rccm.201406-1031OC.
PMID: 25664391
citation: Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.
PMID: 32171076
citation: Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
PMID: 32139904
citation: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
PMID: 32031570
citation: Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002.
PMID: 10075613
citation: Rubak P, Villadsen K, Hvas AM. Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb Res. 2012 Sep;130(3):420-3. doi: 10.1016/j.thromres.2012.06.017. Epub 2012 Jul 17.
PMID: 22809844
responsible party type: Principal Investigator
investigator affiliation: University of Sao Paulo
investigator full name: Jose Carlos Nicolau
investigator title: Director of Coronary Care Unit
mesh term: COVID-19
sharing ipd: No